CK7, CK20, CDX2 and MUC2 immunohistochemical staining used to distinguish metastatic colorectal carcinoma involving ovary from primary ovarian mucinous adenocarcinoma

Japanese Journal of Clinical Oncology

Volumn 40, Issue 3, 2009, Pages 208-213

  Shin, Jung Ha ^a   Bae, Jeong Hoon ^a   Lee, Ahwon ^a   Jung, Chan Kwon ^a   Yim, Hyeon Woo ^a   Park, Jong Sup ^a   Lee, Kyo Young ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

Adenocarcinoma; Mucinous; Neoplasm metastasis; Ovarian neoplasms

Indexed keywords

2 METHYLACYL COENZYME A RACEMASE; CYTOKERATIN 20; CYTOKERATIN 7; MUCIN 2; MUCIN 5AC; PROTEIN CEA; TRANSCRIPTION FACTOR CDX2; TUMOR MARKER; UNCLASSIFIED DRUG; CDX2 PROTEIN, HUMAN; HOMEODOMAIN PROTEIN; MUC2 PROTEIN, HUMAN;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; COLORECTAL CARCINOMA; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MEDICAL HISTORY; METASTASIS; OVARY ADENOCARCINOMA; PROTEIN EXPRESSION; CANCER STAGING; CLASSIFICATION; COLLOID CARCINOMA; COLORECTAL TUMOR; ENZYME IMMUNOASSAY; MALE; METABOLISM; MIDDLE AGED; OVARY TUMOR; PATHOLOGY; PROGNOSIS; SURVIVAL RATE; TISSUE MICROARRAY;

ADENOCARCINOMA, MUCINOUS; ADOLESCENT; ADULT; AGED; COLORECTAL NEOPLASMS; DIAGNOSIS, DIFFERENTIAL; FEMALE; HOMEODOMAIN PROTEINS; HUMANS; IMMUNOENZYME TECHNIQUES; KERATIN-20; KERATIN-7; MALE; MIDDLE AGED; MUCIN-2; NEOPLASM STAGING; OVARIAN NEOPLASMS; PROGNOSIS; SURVIVAL RATE; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 77950361324     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyp150     Document Type: Article

References (24)

1. Tavassoli FA, Devilee P, editors. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. Lyon: IARC Press 2003;193-6.
2. Young RH, Scully RE. Metastatic tumors of the ovary. In: Kurman RJ, editors. Blaustein's Pathology of the Female Genital Tract. 5th edn. New York: Springer 2002;1063-101.
3. Bae JH, Lee AW, Tong SY, Park YG, Namkoong SE, Park JS. Preoperative and postoperative characteristics of metastatic ovarian cancers: experiences with 112 Korean women. J Korean Med Sci 2009;24:114-9.
4. Lash RH, Hart WR. Intestinal adenocarcinomas metastatic to the ovaries. A clinicopathologic evaluation of 22 cases. Am J Surg Pathol 1987;11:114-21.
5. Esteva FJ, Sahin AA, Cristofanilli M, Arun B, Hortobagyi GN. Molecular prognostic factors for breast cancer metastasis and survival. Semin Radiat Oncol 2002;12:319-28.
6. Nishizuka S, Chen S-T, Gwadry FG, Alexander J, Major SM, Scherf U, et al. Diagnostic markers that distinguish colon and ovarian adenocarcinomas: identification by genomic, proteomic, and tissue array profiling. Cancer Res 2003;63:5243-50.
7. Moertel CG. Chemotherapy for colorectal cancer. N Engl J Med 1994;330:1136-42.
8. Qazi F, McGuire WP. The treatment of epithelial ovarian cancer. CA Cancer J Clin 1995;45:88-101.
9. Vang R, Gown AM, Wu L-S-F, Barry TS, Wheeler DT, Yemelyanova A, et al. Immunohistochemical expression of CDX2 in primary ovarian mucinous tumors and metastatic mucinous carcinomas involving the ovary: comparison with CK20 and correlation with coordinate expression of CK7. Mod Pathol 2006;19:1421-8.
10. Prat J. Pathology of the Ovary. Philadelphia: Saunders 2004;295-316.
11. McCluggage WG, Wilkinson N. Metastatic neoplasms involving the ovary: a review with an emphasis on morphological and immunohistochemical features. Histopathology 2005;47:231-47.
12. Lagendijk JH, Mullink H, Van Diest PJ, Meijer GA, Meijer P. Tracing the origin of adenocarcinomas with unknown primary using immunohistochemistry: differential diagnosis between colonic and ovarian carcinomas as primary sites. Hum Pathol 1998;29:491-7.
13. Lagendijk JH, Mullink H, Van Diest PJ, Meijer GA, Meijer CJ. Immunohistochemical differentiation between primary adenocarcinomas of the ovary and ovarian metastases of colonic and breast origin. Comparison between a statistical and an intuitive approach. J Clin Pathol 1999;52:283-90.
14. Vang R, Gown AM, Barry TS, Wheeler DT, Yemelyanova A, Seidman JD, et al. Cytokeratins 7 and 20 in primary and secondary mucinous tumors of the ovary: analysis of coordinate immunohistochemical expression profiles and staining distribution in 179 cases. Am J Surg Pathol 2006;30:1130-9.
15. Lee ES, Cho HD, Kim I. The usefulness of cytokeratin 7 and colon ovarian tumor antigen in the differential diagnosis of primary and metastatic ovarian tumors. Korean J Pathol 1998;32:201-7.
16. Ji H, Isacson C, Seidman JD, Kurman RJ, Ronnett BM. Cytokeratins 7 and 20, Dpc 4, and MUC5AC in the distinction of metastatic mucinous carcinoma in the ovary from primary ovarian mucinous tumors: Dpc 4 assists in identifying metastatic pancreatic carcinomas. Int J Gynecol Pathol 2002;21:391-400.
17. Fraggetta F, Pelosi G, Cafici A, Scollo P, Nuciforo P, Viale G. CDX2 immunoreactivity in primary and metastatic ovarian mucinous tumours. Vichows Arch 2003;443:782-6.
18. Tornillo L, Moch H, Diener PA, Lugili A, Singer G. CDX-2 immunostaining in primary and secondary ovarian carcinomas. J Clin Pathol 2004;57:641-3.
19. Kim MJ. The usefulness of CDX-2 for differentiating primary and metastatic ovarian carcinoma: an immunohistochemical study using a tissue microarray. J Korean Med Sci 2005;20:643-8.
20. Fowler LJ, Maygarden SJ, Novotny DB. Human alveolar macrophage-56 and carcinoembryonic antigen monoclonal antibodies in the differential diagnosis between primary ovarian and metastatic gastrointestinal carcinomas. Hum Pathol 1994;25:666-70.
21. Albarracin CT, Jafri J, Montag AG, Hart J, Kuan SF. Differential expression of MUC2 and MUC5AC Mucin genes in primary ovarian and metastatic colonic carcinoma. Hum Pathol 2000;31:672-7.
22. Logani S, Oliva E, Arnell PM, Amin MB, Young RH. Use of novel immunohistochemical markers expressed in colonic adenocarcinoma to distinguish primary ovarian tumors from metastatic colorectal carcinoma. Mod Pathol 2005;18:19-25.
23. Nassar A, Amin MB, Sexton DG, Cohen C. Utility of alpha-methylacyl coenzyme A racemase (P504S antibody) as a diagnostic immunohistochemical marker for cancer. Appl Immunohistochem Mol Morphol 2005;13:252-5.
24. Went PT, Sauter G, Oberholzer M, Bubendorf L. Abundant expression of AMACR in many distinct tumour types. Pathology 2006;38:426-32.